Treatment of Helicobacter pylori with nitazoxanide-containing regimens: a systematic review

References

• Ahn HJ, Lee DS. Helicobacter pylori in gastric carcinogenesis. World J Gastrointest Oncol. 2015;7:455–465.
   PubMed Web of Science ®Google Scholar
• IARC Working Group on the Evaluation of carcinogenic risks to humans. IARC monographs on the evaluation of carcinogenic risks to humans. Vol 61. Schistosomes, liver flukes and Helicobacter pylori. Geneva: World Health Organization, 1994. p. 45–119.
   Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–1953.
   PubMed Web of Science ®Google Scholar
• Sokic-Milutinovic A, Alempijevic T, Milosavljevic T. Role of Helicobacter pylori infection in gastric carcinogenesis: current knowledge and future directions. World J Gastroenterol. 2015;21:11654–11672.
   PubMed Web of Science ®Google Scholar
• Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212–239.
   PubMed Web of Science ®Google Scholar
• Fagoonee S, Pellicano R. Helicobacter pylori: molecular basis for colonization and survival in gastric environment and resistance to antibiotics. A short review. Infect Dis (Lond). 2019;51:399–408.
   PubMed Web of Science ®Google Scholar
• Megraud F, Coenen S, Versporten A, et al.; on behalf of the Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34–42.
   PubMed Web of Science ®Google Scholar
• Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155:1372–1382.
   PubMed Web of Science ®Google Scholar
• Ierardi E, Giorgio F, Losurdo G, et al. How antibiotic resistances could change Helicobacter pylori treatment: a matter of geography? World J Gastroenterol. 2013;19:8168–8180.
   PubMed Web of Science ®Google Scholar
• Sisson G, Goodwin A, Raudonikiene A, et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother. 2002;46:2116–2123.
   PubMed Web of Science ®Google Scholar
• Nitazoxanide (Alinia) [package insert]. Tampa (FL): Romark, LC; 2018.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.
   PubMedGoogle Scholar
• Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712–716.
   PubMed Web of Science ®Google Scholar
• Shehata MA, Talaat R, Soliman S, et al. Randomized controlled study of a novel triple nitazoxanide (NTZ)-containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infection. Helicobacter. 2017;22:e12395.
   Web of Science ®Google Scholar
• Abd-Elsalam S, Kobtan A, El-Kalla F, et al. A 2-week nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: a single center experience. Medicine (Baltimore). 2016;95:e3879.
   PubMed Web of Science ®Google Scholar
• Basu PP, Rayapudi K, Pacana T, et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011;106:1970–1975.
   PubMed Web of Science ®Google Scholar
• Guttner Y, Windsor HM, Viiala CH, et al. Nitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study. Antimicrob Agents Chemother. 2003;47:3780–3783.
   PubMed Web of Science ®Google Scholar
• Mégraud F, Occhialini A, Rossignol JF. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother. 1998;42:2836–2840.
   PubMed Web of Science ®Google Scholar
• Ramos-Soriano AG, Black J. Nitazoxanide use as part of an empiric multi-drug regimen in treating children with suspected Helicobacter pylori Infection. Case Rep Gastroenterol. 2015;9:36–42.
   PubMedGoogle Scholar
• Basu P, Shah N, Rahaman MD, et al. Rifabutin, omeprazole, alinia, and doxycycline therapy for prior treatment failure helicobacter pylori population: a randomized, open-label clinical pilot study road trial. Am J Gastroenterol. 2013;108:S49.
   PubMed Web of Science ®Google Scholar
• Basu PP, Krishnaswamy N, Korapati R, et al. A new ultra short regimen with dexlansoprazole, moxifloxacin, amoxicillin, nitazoxanide, and doxycycline (DeMAND) in eradication of Helicobacter pylori: an open-label randomized clinical trial. Int J Infect Dis. 2010;14:S52.
   Web of Science ®Google Scholar
• Sharma V, Sharma R, Rizwani P, et al. Initial experience with modified quadruple treatment regimen containing doxycycline, levofloxacin, nitazoxanide for Helicobacter pylori eradication. Indian J Gastroenterol. 2010;29:14.
   Google Scholar
• Stuppy W. Dual therapy: nitazoxanide and sucralfate for the treatment of Helicobacter pylori. Am J Gastroenterol. 2010;105:S45–S46.
   Web of Science ®Google Scholar
• Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514–533.
   PubMed Web of Science ®Google Scholar
• Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419–434.
   PubMed Web of Science ®Google Scholar
• Bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (Pylera) [package insert]. Madison (NJ): Allergan USA.; 2018.
   Google Scholar
• Watson JB, Moss SF. Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. Am J Gastroenterol. 2011;106:1976–1977.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;12:CD008337.
   PubMedGoogle Scholar
• Gatta L, Vakil N, Ricci C, et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol. 2004;99:823–829.
   PubMed Web of Science ®Google Scholar